A feasibility study to establish recruitment and immunmonitoring for a first in man study of a therapeutic H. pylori vaccine in healthy infected volunteers

H. pylori colonizes the stomach of about half of the world's population. The infection is acquired in early childhood and remains asymptomatic in the vast majority of infected individuals. Although the infection elicits a strong inflammatory response, the bacterium cannot be cleared by the immune system. This chronic infection is a prerequisite for the development of gastric adenocarcinomas, leading to considerable morbidity and mortality. The high prevalence of the infection and the rapid emergence of antibiotic resistance implicate the need for an H. pylori vaccine. IMX101 is a vaccine that is being developed…